Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats

References

• Agueros M, Zabaleta V, Espuelas S, et al. (2010). Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 145:2–8
   PubMed Web of Science ®Google Scholar
• Cai S, Yang Q, Bagby TR, et al. (2011). Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 63:901–8
   PubMed Web of Science ®Google Scholar
• Caliph SM, Charman WN, Porter CJ. (2000). Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89:1073–84
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJ. (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev 19:149–69
   Web of Science ®Google Scholar
• Charman WNA, Stella VJ. (1986a). Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport DDT. Int J Pharm 33:165–72
   Web of Science ®Google Scholar
• Charman WNA, Stella VJ. (1986b). Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 34:175–8
   Web of Science ®Google Scholar
• Choi JS, Li XG. (2005). The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharm Sci 24:95–100
   PubMed Web of Science ®Google Scholar
• Fisher GA, Sikic BI. (1995). Clinical-studies with modulators of multidrug-resistance. Hematol Oncol Clin N Am 9:363–82
   PubMed Web of Science ®Google Scholar
• Gao P, Rush BD, Pfund WP, et al. (2003). Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 92:2386–98
   PubMed Web of Science ®Google Scholar
• Garzonaburbeh A, Poupaert JH, Claesen M, et al. (1983). 1,3-Dipalmitoylglycerolester of chlorambucil as a lymphotropic, orally administrable anti-neoplastic agent. J Med Chem 26:1200–3
   PubMed Web of Science ®Google Scholar
• Ge H, Wang J, Kayser MM, et al. (2008). Synthesis, tubulin assembly, and antiproliferative activity against MCF7 and NCI/ADR-RES cancer cells of 10-O-acetyl-5′-hydroxybutitaxel. Bioorg Med Chem Lett 18:6165–7
   PubMed Web of Science ®Google Scholar
• Griffin BT, O'Driscoll CM. (2008). An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat. Pharm Res 25:1125–33
   PubMed Web of Science ®Google Scholar
• Holm R, Mullertz A, Pedersen GP, et al. (2001). Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm Res 18:1299–304
   PubMed Web of Science ®Google Scholar
• Kemper EM, van Zandbergen AE, Cleypool C, et al. (2003). Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849–55
   PubMed Web of Science ®Google Scholar
• Krishnaiah YSR, Khan MA. (2012). Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer. Pharm Dev Technol 17:521–40
   PubMed Web of Science ®Google Scholar
• Lee CK, Choi JS. (2010). Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 85:350–6
   PubMed Web of Science ®Google Scholar
• Ling SSN, Magosso E, Khan NAK, et al. (2006). Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 32:335–45
   PubMed Web of Science ®Google Scholar
• Liu J, Meisner D, Kwong E, et al. (2009). Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res 69:1174–81
   PubMed Web of Science ®Google Scholar
• Lo J, Chen B, Lee T, et al. (2010). Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants. J Pharm Sci 99:2320–32
   PubMed Web of Science ®Google Scholar
• Malingre MM, Beijnen JH, Rosing H, et al. (2001a). The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anti-Cancer Drugs 12:351–8
   PubMed Web of Science ®Google Scholar
• Malingre MM, Beijnen JH, Schellens JHM. (2001b). Oral delivery of taxanes. Investig New Drugs 19:155–62
   PubMed Web of Science ®Google Scholar
• Murota K, Cermak R, Terao J, et al. (2013). Influence of fatty acid patterns on the intestinal absorption pathway of quercetin in thoracic lymph duct-cannulated rats. Br J Nutr 109:2147–53
   PubMed Web of Science ®Google Scholar
• Nornoo AO, Zheng H, Lopes LB, et al. (2009). Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 71:310–7
   PubMed Web of Science ®Google Scholar
• O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15:405–15
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Buckle T, Lambert G, et al. (2011). Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investig New Drugs 29:768–76
   PubMed Web of Science ®Google Scholar
• Park JH, Park JH, Hur HJ, et al. (2012). Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci 45:296–301
   PubMed Web of Science ®Google Scholar
• Peltier S, Oger J M, Lagarce F, et al. (2006). Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243–50
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman SA, Charman WN. (1996). Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci 85:351–6
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. (1997). Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev 25:71–89
   Web of Science ®Google Scholar
• Porter CJ, Charman WN. (2001). Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50:61–80
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231–48
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. (1995). Drug–therapy–paclitaxel (Taxol). N Engl J Med 332:1004–14
   PubMed Web of Science ®Google Scholar
• Skobe M, Hawighorst T, Jackson DG, et al. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–8
   PubMed Web of Science ®Google Scholar
• Sparreboom A, vanAsperen J, Mayer U, et al. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–5
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular-localization of the multidrug-resistance gene-product P-glycoprotein in norma human-tissues. Proc Natl Acad Sci USA 84:7735–8
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. (2008). Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60:702–16
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. (2010a). Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Mol Pharm 7:2297–309
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Shanker RM, Charman WN, et al. (2010b). The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res 27:1949–64
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. (2001). Role of formulation vehicles in taxane pharmacology. Investig New Drugs 19:125–41
   PubMed Web of Science ®Google Scholar
• Woo JS, Lee CH, Shim CK, et al. (2003). Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24–30
   PubMed Web of Science ®Google Scholar
• Yang SC, Gursoy RN, Lambert G, et al. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261–70
   PubMed Web of Science ®Google Scholar